Remedy Robotics Raises $62M to Advance AI Cardiovascular Care
Remedy Robotics Raises $62M Series B Funding Remedy Robotics, a developer of a robotic platform for cardiovascular care, closed a $62 million Series B funding round. The financing was announced The post Remedy Robotics Raises $62M to Advance AI Cardiovascular Care appeared first on Ventureburn .
Remedy Robotics, a San Francisco-based company specializing in robotic platforms for cardiovascular care, has successfully raised $62 million in a Series B funding round. The investment, led by DCVC, was announced on November 16, 2026. Existing investors, including KdT Ventures, Divergent Capital, Blackbird, Build Collective by Tony Fadell, and Hostplus, also participated.
New investors, UC Investments and Skip Capital, added to the round. The funds will be utilized for a significant clinical trial in collaboration with the University of California and to advance the N1 System towards US Food and Drug Administration approval. The N1 System, which integrates robotic hardware and machine learning software, is designed for both on-site and remote operations, capable of performing neurovascular, coronary, and peripheral vascular care.
With over 100 hospital partnerships globally, Remedy is also the exclusive robotic partner for SVIN Mission Thrombectomy. The Series B funding will allow Remedy to accelerate its clinical development efforts, focusing on prototype deployment trials with clinical partners and enhancing its hardware, software, and machine-learning capabilities.
Cardiovascular diseases remain the leading cause of death worldwide, claiming an estimated 19.8 million lives in 2022, according to the World Health Organization. Remedy aims to make specialized cardiovascular intervention more accessible by overcoming the current limitations, with only 2.8 percent of patients worldwide eligible for endovascular therapy.
Written by urgent.news from Ventureburn's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.